论文部分内容阅读
目的探讨纳洛酮在治疗新生儿呼吸衰竭中的应用价值及其安全性。方法将发生呼吸衰竭的新生儿64例随机分成2组,治疗组34例,对照组30例。2组临床资料相比差异无统计学意义。治疗组采用纳洛酮治疗,对照组采用东莨菪碱治疗。结果治疗组34例患儿治愈25例,治愈率73.5%;对照组30例患儿治愈16例,治愈率53.3%,2组治愈率比较差异有统计学意义(P<0.05)。治疗组在用药后8～12 h PaCO2迅速下降,24～48 h PaO2迅速上升,与对照组比较差异有统计学意义(P<0.05)。结论纳洛酮治疗新生儿呼吸衰竭疗效肯定,安全性好。
Objective To investigate the value and safety of naloxone in the treatment of neonatal respiratory failure. Methods Sixty-four neonates with respiratory failure were randomly divided into two groups: 34 cases in the treatment group and 30 cases in the control group. There was no significant difference between the two groups in clinical data. The treatment group was treated with naloxone, while the control group was treated with scopolamine. Results In the treatment group, 34 cases were cured in 25 cases, the cure rate was 73.5%. In the control group, 30 cases were cured in 16 cases, the cure rate was 53.3%. There was significant difference in the cure rate between the two groups (P <0.05). In the treatment group, the PaCO2 decreased rapidly from 8 to 12 h after treatment and the PaO2 increased rapidly from 24 to 48 h after the treatment, which was significantly different from the control group (P <0.05). Conclusion Naloxone treatment of neonatal respiratory failure with positive effect, good safety.